Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.

Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T

Current medical research and opinion17 Jan 2013Cited by 19 (Europe PMC)

PMID23259702DOI10.1185/03007995.2012.761956PepBankPUB-23259702

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporosis follow-up, prior teriparatide with subsequent treatment was linked to fewer new vertebral fractures than prior placebo with subsequent treatment.
In plain wordsIn osteoporosis follow-up, prior teriparatide and subsequent treatment were linked to fewer new vertebral fractures than prior placebo and subsequent treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNew morphometric vertebral fractures during follow-up
Study
n = 444
Comparator
Post-placebo group with subsequent treatment
Outcome group
Bone and joint · Musculoskeletal
Measurements
Vertebral fracture incidence
3.4%
post-teriparatide
Vertebral fracture incidence
13.7%
post-placebo
Relative risk
0.23 ratio
post-teriparatide versus post-placebo
Relative risk 95% CI
0.1 to 0.52 ratio
post-teriparatide versus post-placebo
Patients with new morphometric vertebral fracture
7 patients
post-teriparatide (of 203)
Patients with new morphometric vertebral fracture
33 patients
post-placebo (of 241)
Source sentences
Summary
In the 1 year follow-up period, new morphometric vertebral fractures occurred in 7/203 (3.4%) in the post-teriparatide group and 33/241 (13.7%) in the post-placebo group (relative risk [RR]: 0.23, 95% confidence interval [CI]: 0.10 to 0.52, P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
After 72 weeks of teriparatide injections or placebo (original trial), treatment was unblinded and subjects were subsequently treated with bisphosphonates or other therapeutic regimens at the discretion of their physicians and followed for 1 year.
Summary · context
This study was an observational follow-up study and the regimens of subsequent medication after discontinuation of the original TOWER trial were not randomly allocated.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2325970201
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporosis follow-up, cumulative vertebral fracture incidence was lower after teriparatide followed by subsequent treatment than after placebo followed by subsequent treatment.
In plain wordsIn osteoporosis follow-up, cumulative vertebral fractures were less frequent after teriparatide and subsequent treatment than after placebo and subsequent treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCumulative vertebral fracture incidence
Study
n: not reported in source
Comparator
Original placebo followed by subsequent treatment
Outcome group
Bone and joint · Musculoskeletal
Measurements
Cumulative incidence
4.9%
post-teriparatide
Cumulative incidence
22.8%
post-placebo
Relative risk
0.18 ratio
cumulative incidence comparison
Relative risk 95% CI
0.09 to 0.36 ratio
cumulative incidence comparison
Source sentences
Summary
The cumulative incidences from the start of the original trial were 4.9% and 22.8%, respectively (RR: 0.18, 95% CI: 0.09 to 0.36, P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
In the 1 year follow-up period, new morphometric vertebral fractures occurred in 7/203 (3.4%) in the post-teriparatide group and 33/241 (13.7%) in the post-placebo group (relative risk [RR]: 0.23, 95% confidence interval [CI]: 0.10 to 0.52, P < 0.05).
Summary · context
After 72 weeks of teriparatide injections or placebo (original trial), treatment was unblinded and subjects were subsequently treated with bisphosphonates or other therapeutic regimens at the discretion of their physicians and followed for 1 year.
Summary · context
This study was an observational follow-up study and the regimens of subsequent medication after discontinuation of the original TOWER trial were not randomly allocated.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2325970202
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporosis follow-up, lumbar spine BMD increased further in subjects receiving subsequent bisphosphonates.
In plain wordsIn patients with osteoporosis, spine bone density increased during subsequent bisphosphonate treatment compared with the follow-up baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD during subsequent bisphosphonates
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD increase
9.6%
lumbar spine during subsequent bisphosphonates
Source sentences
Summary
In subjects treated with bisphosphonates, mean BMD values further significantly increased by 9.6%, 2.9%, and 4.1% at the lumbar spine, femoral neck, and total hip, respectively (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
After 72 weeks of teriparatide injections or placebo (original trial), treatment was unblinded and subjects were subsequently treated with bisphosphonates or other therapeutic regimens at the discretion of their physicians and followed for 1 year.
Summary · context
This study was an observational follow-up study and the regimens of subsequent medication after discontinuation of the original TOWER trial were not randomly allocated.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2325970203
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporosis follow-up, femoral neck BMD increased further in subjects receiving subsequent bisphosphonates.
In plain wordsIn patients with osteoporosis, femoral neck density increased during subsequent bisphosphonate treatment compared with the follow-up baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD during subsequent bisphosphonates
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD increase
2.9%
femoral neck during subsequent bisphosphonates
Source sentences
Summary
In subjects treated with bisphosphonates, mean BMD values further significantly increased by 9.6%, 2.9%, and 4.1% at the lumbar spine, femoral neck, and total hip, respectively (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
After 72 weeks of teriparatide injections or placebo (original trial), treatment was unblinded and subjects were subsequently treated with bisphosphonates or other therapeutic regimens at the discretion of their physicians and followed for 1 year.
Summary · context
This study was an observational follow-up study and the regimens of subsequent medication after discontinuation of the original TOWER trial were not randomly allocated.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2325970204
05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporosis follow-up, total hip BMD increased further in subjects receiving subsequent bisphosphonates.
In plain wordsIn patients with osteoporosis, hip bone density increased during subsequent bisphosphonate treatment compared with the follow-up baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD during subsequent bisphosphonates
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD increase
4.1%
total hip during subsequent bisphosphonates
Source sentences
Summary
In subjects treated with bisphosphonates, mean BMD values further significantly increased by 9.6%, 2.9%, and 4.1% at the lumbar spine, femoral neck, and total hip, respectively (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
After 72 weeks of teriparatide injections or placebo (original trial), treatment was unblinded and subjects were subsequently treated with bisphosphonates or other therapeutic regimens at the discretion of their physicians and followed for 1 year.
Summary · context
This study was an observational follow-up study and the regimens of subsequent medication after discontinuation of the original TOWER trial were not randomly allocated.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2325970205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.